RS-0337

RS-0337 is a preclinical, investigational small molecule oncology drug developed by RS Research. It is the lead candidate for the Sagitta Dui platform, a proprietary biodegradable conjugation technology designed to optimize the therapeutic index of cancer treatments. The Sagitta Dui platform forms micellar nanoparticles upon contact with water, encapsulating its payload and enabling dual drug loading for potential synergistic effects. This approach aims to improve efficacy, pharmacokinetics (notably prolonging circulation time), and manufacturability compared to native active pharmaceutical ingredients. RS-0337 specifically targets HER2 (human epidermal growth factor receptor 2) and is being developed primarily for oncology indications such as breast cancer and stomach cancer[1][2][4].

Other names

Sagitta Dui lead candidate